Ambulatory BP Monitoring vs Office BP

Slides:

Advertisements

Similar presentations

Treatment of hypertension: What are the new standards of care?

Advertisements

1 Mark Huffman, MD, MPH Northwestern University Feinberg School of Medicine Northwestern Memorial Hospital Healthy Transitions 21 November 2013 Blood Pressure.

Trademarks may be registered and are the property of their respective owners. Today’s discussion may regard information or indications not evaluated by.

Update on hypertension - diagnosis, monitoring and guideline treatment targets Prof. Richard McManus, Birmingham, United Kingdom.

TROPHY TRial Of Preventing HYpertension. High-normal BP increases CV risk Vasan RS et al. N Engl J Med. 2001;345: Incidence of CV events in women.

DynaPulse Non-invasive Blood pressure and Hemodynamic Monitoring Example Applications: Cardiac Rhythm & Hypertension Managements Pulse.

HOME AND AMBULATORY BLOOD PRESSURE MONITORING

Journal Club ADAM WILCOX, PHARMD 1/22/14. Patient Case  DB, 70 yo M  Overall ABPM summary  Avg. BP = 116/62  Daytime = 120/63  Nighttime = 103/58.

Definitions and classification of office blood pressure levels (mmHg) Modified by ESC Guidelines 2013 CARDIOcheckAPP.

10/5/2015. Hypertension GuidelinesDate JNC JNC JNC NICE Guidelines 2011 ESC / ESH Hypertension Guidelines ESC Guideline2007.

The TRial Of Preventing HYpertension (TROPHY) TROPHY.

DynaPulse Non-invasive Blood pressure and Hemodynamic Monitoring Example Applications: Cardiac Rhythm & Hypertension Managements Pulse.

A Controlled Trial of Renal Denervation for Resistant Hypertension

Objective: To asses the efficacy of hydrochlorothiazide on 24-h blood pressure (BP) control.Methods: Review of all the randomized trials that assessed.

Liraglutide Promotes Natriuresis but Does Not Increase Circulating Levels of Atrial Natriuretic Peptide in Hypertensive Subjects With Type 2 Diabetes Featured.

Empagliflozin Reduces Blood Pressure in Patients With Type 2 Diabetes and Hypertension Featured Article: Ilkka Tikkanen, Kirsi Narko, Cordula Zeller, Alexandra.

Short Sleep Duration as a Predictor of Cardiovascular Events Summary and Comment by Jamaluddin Moloo, MD, MPH Published in Journal Watch General Medicine.

Canagliflozin Cardiovascular Safety. 2 Potential CV protection pathways of SGLT2i Diab Vasc Dis Res Mar;12(2):

The MICRO-HOPE. Microalbuminuria, Cardiovascular and Renal Outcomes in the Heart Outcomes Prevention Evaluation Reference Heart Outcomes Prevention Evaluation.

Date of download: 5/29/2016 Copyright © The American College of Cardiology. All rights reserved. From: Impact of Renal Denervation on 24-Hour Ambulatory.

Date of download: 5/29/2016 Copyright © The American College of Cardiology. All rights reserved. From: Renal Denervation in Moderate Treatment-Resistant.

The Heart Outcomes Prevention Evaluation (HOPE) – 3 Trial

Journal Club February 7, 2014 Sadie T. Velásquez, MD.

Date of download: 7/6/2016 Copyright © The American College of Cardiology. All rights reserved. From: Externally Delivered Focused Ultrasound for Renal.

Date of download: 7/9/2016 Copyright © The American College of Cardiology. All rights reserved. From: Making Sense of Statistics in Clinical Trial Reports:

Powered by Infomedica Infomedica Conference Coverage* of 26 th European Meeting on Hypertension and Cardiovascular Protection Paris (France), June 10-13,

Dr John Cox Diabetes in Primary Care Conference Cork

Update on therapy-resistant hypertension:

ACCORD Design and Baseline Characteristics

Figure 1. Schedule of the study

From ESH 2016 | POS 3C: Chiara Lorenzi, MD

A.M. Thompson, T.G. Pickering Kidney International

Copyright © 2010 American Medical Association. All rights reserved.

Thomas G. Pickering, MD, DPhil, William B. White, MD

FDA Pathway to Approval: Clinical Requirements for Renal Denervation

Eoin O’Brien, DSc, MD, Eamon Dolan, MD, FRCPI Clinical Therapeutics

From ESH 2016 | POS 7D: Jan Rosa, MD

Felix Mahfoud Saarland University Hospital, Homburg, Germany

Baseline Demographic and Clinic Variables According to Office vs 24-Hour or Home BP Giuseppe Mancia, et al. Hypertension 2006;47;

Jan B. Pietzsch1, Benjamin P. Geisler1, Murray D. Esler 2

CORAL Trial design: Patients with renal artery stenosis and hypertension or chronic kidney disease were randomized to renal artery stenting (n = 467) vs.

Flowchart of participants

Should SPRINT change our practice?

SYMPLICITY HTN-3: A Prospective, Randomized, Sham-Controlled Trial of Renal Sympathetic Denervation in Patients with Refractory Hypertension: Post Hoc.

Mean 24-Hour, Daytime, and Night Ambulatory Systolic BP, Diastolic BP, and PP Before (Week 0) and After (Week 12) NAG and Placebo Intake in 37 Hypertensive.

Neuro-Hormonal vs Structural Hypertension why they require different approaches Paul A. Sobotka Chief Medical Officer Rox Medical, Inc.

The Ardian Catheter Based Approach to Renal Denervation to Treat Refractory HTN: Results of the EU Randomized Clinical Trial Krishna Rocha-Singh, M.D.,

(B.P :51) ( B:P52 ).

CVRx Baroreflex Activation Therapy:

Isolated Systolic Hypertension: An Update After SPRINT

Renal Denervation Two Late-Breaking Clinical Trials.

Systolic Blood Pressure Intervention Trial (SPRINT)

Cholesterol and blood pressure values at baseline and after 15 days of dark-chocolate and white-chocolate consumption Characteristic Dark chocolate before.

Select Topics in Cardiovascular Medicine

Managing Complex Hypertension: What Every Physician Should Know

Section VIII. Ambulatory BP Measurement

Management of perioperative hypertension

Managing Hard-To-Treat Hypertension: What Every Physician Should Know

Resistant Hypertension: Initial Combinations of Medications

Hypertension Guidelines

Controlling High Blood Pressure

Volume 93, Issue 1, Pages (January 2018)

Controlling Elevated Blood Pressure

Life expectancy and baseline BP: Male participants

Ambulatory BP Monitoring vs Office BP

Volume 377, Issue 9771, Pages (March 2011)

DENERHTN Trial design: Patients with resistant hypertension were randomized to renal denervation plus standardized stepped-care antihypertensive treatment.

Isolated Systolic Hypertension: An Update After SPRINT

Effects of placebo or carvedilol CR on 24-hour mean systolic blood pressure and diastolic blood pressure obtained by ambulatory monitoring in hypertensive.

Role of - Azilsartan - Azilsartan/chlorthalidone

Presentation transcript:

Ambulatory BP Monitoring vs Office BP

ASH/AHA: Suggested Values for the Upper Limit of Normal Ambulatory Pressure

ESC/ESH: Definitions of Hypertension by Office and Out-of-Office BP Levels

Disparities for Changes in Clinic and Ambulatory BP in Placebo Group in a Clinical Trial

Meta-Analysis of 44 Studies Comparing Changes in Office vs Ambulatory BP

Higher Baseline Office BP Results in Greater Reductions vs ABPM

Changes in Office BP After Renal Denervation

Changes in ABPM After Renal Denervation

SHEP: Reductions in SBP Reduce Stroke